CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向 B7-H3 的免疫治疗在神经母细胞瘤中的希望
英文原题：Hopes on immunotherapy targeting B7-H3 in neuroblastoma.
查看英文原题
Hopes on immunotherapy targeting B7-H3 in neuroblastoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
神经母细胞瘤是儿童中最具侵袭性的癌症之一，临床表现高度异质，从自发消退到高度转移均有可能。高危神经母细胞瘤是所有儿童癌症中死亡率最高的类型，凸显开发有效新疗法的紧迫性。免疫检查点蛋白B7-H3在神经母细胞瘤中高表达，并参与致癌信号、肿瘤细胞可塑性和耐药。免疫检查点抑制疗法已改善多种人类癌症患者的生存；近期研究还提供临床前证据，显示靶向B7-H3治疗神经母细胞瘤可能获益，尤其是新型CAR-T 和CAR-NK细胞策略。本文总结神经母细胞瘤靶向治疗现状，重点介绍B7-H3作为高危神经母细胞瘤新型免疫调节治疗靶点的潜力。
展开英文摘要原文
Neuroblastoma is one of the most aggressive cancer forms in children, with highly heterogenous clinical manifestations ranging from spontaneous regression to high metastatic capacity. High-risk neuroblastoma has the highest mortality rates of all pediatric cancers, highlighting the urgent need for effective novel therapeutic interventions.
B7-H3 immune checkpoint protein is highly expressed in neuroblastoma, and it is involved in oncogenic signaling, tumor cell plasticity, and drug resistance. Immunotherapies based on immune checkpoint inhibition have improved patient survival in several human cancers, and recent reports provide preclinical evidence on the benefits of targeting B7-H3 in neuroblastoma, with emphasis on novel CAR T/NK-cell approaches.
Here, we summarize the current status of neuroblastoma targeted therapies, with a focus on B7-H3 as a promising novel immunoregulatory therapeutic target for high-risk neuroblastoma.
论文信息
- 作者
- Pulido R、Nunes-Xavier CE
- 第一作者单位
- Biomarkers in Cancer, Biocruces Bizkaia Health Research Institute, Spain; IKERBASQUE, Basque Foundation for Science, Spain.Spain
- 通讯作者单位
- Biomarkers in Cancer, Biocruces Bizkaia Health Research Institute, Spain; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Norway. Electronic address: carolinenunesxavier@gmail.com.Spain
- 期刊
- Translational oncology2023 Jan
- 原文标识
- PubMed 36327699 · DOI 10.1016/j.tranon.2022.101580
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →